ElÅ¼bieta Senkus

List of Publications by Year
in descending order

77 papers	9,999 citations	126708 33 h-index	85405 71 g-index
81 all docs	81 docs citations	81 times ranked	11846 citing authors

#	Article	IF	Citations
1	European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncology, The, 2022, 23, e21-e31.	5.1	117
2	High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series. Pathology, 2022, 54, 269-278.	0.3	4
3	Management Strategies for Hyperglycemia Associated with the Î±-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers, 2022, 14, 1598.	1.7	16
4	Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review. Cancer Treatment Reviews, 2022, 105, 102364.	3.4	8
5	miRNA signatures of prognostic significance in single hormone receptor-positive breast cancer.. Journal of Clinical Oncology, 2022, 40, e12544-e12544.	0.8	0
6	EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).. Journal of Clinical Oncology, 2022, 40, TPS1109-TPS1109.	0.8	2
7	Comparison of claudin-3 and claudin-4 expression in bilateral and unilateral breast cancer. Neoplasma, 2021, 68, 283-289.	0.7	2
8	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.. Journal of Clinical Oncology, 2021, 39, LBA1-LBA1.	0.8	26
9	Lost but Not Leastâ€"Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer. Cancers, 2021, 13, 4755.	1.7	7
10	Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treatment Reviews, 2021, 100, 102264.	3.4	29
11	De-escalation of axillary irradiation for early breast cancer â€“ Has the time come?. Cancer Treatment Reviews, 2021, 101, 102297.	3.4	16
12	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open, 2020, 5, e000793.	2.0	113
13	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Statusâ€"A Pilot Study. Diagnostics, 2020, 10, 617.	1.3	7
14	The requirements of a specialist breast centre. Breast, 2020, 51, 65-84.	0.9	111
15	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast, 2020, 52, 8-16.	0.9	188
16	ER-/PgR+ breast cancer is a separate entity characterized by distinct phenotype: Comprehensive reevaluation of cases from Polish and Hungarian centers.. Journal of Clinical Oncology, 2020, 38, e12554-e12554.	0.8	2
17	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer, 2019, 120, 20-30.	1.3	75
18	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianâ€™s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology, 2019, 30, 558-566.	0.6	493

#	Article	IF	Citations
19	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1194-1220.	0.6	1,241
20	ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiotherapy and Oncology, 2019, 137, 159-166.	0.3	80
21	Locally Advanced Breast Cancer. , 2018, , 567-578.		0
22	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
23	Estrogen receptor-negative progesterone receptor-positive breast cancer â€“ â€œNobody's landâ€ or just an artifact?. Cancer Treatment Reviews, 2018, 67, 78-87.	3.4	46
24	4th ESOâ€“ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 2018, 29, 1634-1657.	0.6	891
25	EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physicianâ€™s choice (TPC) in OlympiAD.. Journal of Clinical Oncology, 2018, 36, 1045-1045.	0.8	3
26	Olaparib versus chemotherapy treatment of physicianâ€™s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.. Journal of Clinical Oncology, 2018, 36, 1052-1052.	0.8	10
27	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation. Histology and Histopathology, 2018, 33, 55-64.	0.5	1
28	3rd ESOâ€“ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	0.6	865
29	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 2017, 377, 523-533.	13.9	2,256
30	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Cancer Treatment Reviews, 2017, 53, 98-110.	3.4	101
31	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast, 2017, 35, 203-217.	0.9	203
32	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of Oncology, 2017, 28, 2481-2488.	0.6	24
33	New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology. ESMO Open, 2017, 2, e000204.	2.0	0
34	Over-treatment in metastatic breast cancer. Breast, 2017, 31, 309-317.	0.9	25
35	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. Journal of Clinical Oncology, 2017, 35, LBA4-LBA4.	0.8	4
36	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. Journal of Clinical Oncology, 2017, 35, LBA4-LBA4.	0.8	28

#	Article	IF	Citations
37	Breast Cancer in Young Women - News from the BCY3 Consensus Conference. Breast Care, 2016, 11, 432-435.	0.8	0
38	Vinflunineâ€“gemcitabine versus vinflunineâ€“carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Annals of Oncology, 2016, 27, 449-454.	0.6	45
39	A call back to reality!. Nature Reviews Clinical Oncology, 2015, 12, 67-68.	12.5	3
40	Management of locally advanced breast cancerâ€"perspectives and future directions. Nature Reviews Clinical Oncology, 2015, 12, 147-162.	12.5	113
41	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 904-910.	0.4	52
42	The need for post-mastectomy radiotherapy in patients with IBC. Nature Reviews Clinical Oncology, 2015, 12, 370-370.	12.5	0
43	First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.. Journal of Clinical Oncology, 2015, 33, 4503-4503.	0.8	5
44	Czy wydÅ‚uÅ¼ona pooperacyjna hormonoterapia powinna byÄ‡ standardowym postÄ™powaniem u chorych na raka piersi? GÅ‚os na TAK. Nowotwory, 2015, 65, 59-61.	0.1	0
45	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology, 2014, 25, 1871-1888.	0.6	402
46	Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pairâ€matched immunohistochemical analysis aimed at intrinsic tumor phenotype. Pathology International, 2014, 64, 508-517.	0.6	3
47	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3â€98. Psycho-Oncology, 2014, 23, 173-182.	1.0	55
48	Synchronous and metachronous metastatic breast cancer â€“ Two incarnations of the same beast?. Breast, 2014, 23, 1.	0.9	4
49	Time for more optimism in metastatic breast cancer?. Cancer Treatment Reviews, 2014, 40, 220-228.	3.4	59
50	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast, 2014, 23, 489-502.	0.9	269
51	Breast cancer units â€“ Improvement in care or expensive â€œwishful thinkingâ€?. Breast, 2014, 23, 199-200.	0.9	2
52	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).. Journal of Clinical Oncology, 2014, 32, 4534-4534.	0.8	2
53	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. International Journal of Clinical and Experimental Pathology, 2014, 7, 353-63.	0.5	9
54	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€“MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast, 2013, 22, 203-210.	0.9	77

#	Article	IF	Citations
55	Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. Breast, 2013, 22, 425-430.	0.9	1
56	Management of Adenoid Cystic Carcinoma of the Breast: A Rare Cancer Network Study. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2118-2124.	0.4	58
57	1st International consensus guidelines for advanced breast cancer (ABC 1). Breast, 2012, 21, 242-252.	0.9	291
58	Cardiovascular effects of systemic cancer treatment. Cancer Treatment Reviews, 2011, 37, 300-311.	3.4	183
59	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. Journal of the National Cancer Institute, 2010, 102, 456-463.	3.0	325
60	Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. Journal of the National Cancer Institute, 2010, 102, 207-208.	3.0	0
61	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. Journal of the National Cancer Institute, 2009, 101, 1174-1181.	3.0	202
62	Sunitinib in breast cancer: Friend or foe. Breast, 2009, 18, 211-212.	0.9	1
63	Phyllodes Tumor of the Breast. International Journal of Radiation Oncology Biology Physics, 2008, 70, 492-500.	0.4	205
64	Exacerbation of diabetes related to exemestane treatment. Acta OncolÃ³gica, 2008, 47, 1167-1169.	0.8	2
65	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annals of Oncology, 2008, 19, 1090-1096.	0.6	168
66	Cardiac Involvement at Presentation of Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 1010-1011.	0.8	19
67	BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncology Reports, 2008, 19, 263-8.	1.2	51
68	Cardiovascular effects of breast cancer radiotherapy. Cancer Treatment Reviews, 2007, 33, 578-593.	3.4	91
69	Outcome and prognostic factors in breast sarcoma: A multicenter study from the rare cancer network. Radiotherapy and Oncology, 2007, 85, 355-361.	0.3	107
70	Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer. Radiotherapy and Oncology, 2006, 79, 304-309.	0.3	17
71	Intraocular malignant teratoid medulloepithelioma in an adult: clinicopathological case report and review of the literature. Acta Ophthalmologica, 2006, 84, 259-262.	0.4	28
72	The effects of tamoxifen on the female genital tract. Cancer Treatment Reviews, 2004, 30, 291-301.	3.4	59

#	Article	IF	Citations
73	Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation. Cancer Treatment Reviews, 2004, 30, 671-682.	3.4	21
74	Second lower genital tract squamous cell carcinoma following cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 765-770.	1.3	3
75	Patient-related factors determining geometry of intracavitary applicators and pelvic dose distribution during cervical cancer brachytherapy. International Journal of Radiation Oncology Biology Physics, 1997, 37, 531-536.	0.4	13
76	Alveolar Rhabdomyosarcoma of the Uterine Cervix. Gynecologic Oncology, 1996, 63, 398-403.	0.6	30
77	Epithelioid Sarcoma of the Bartholin's Gland Primarily Diagnosed as Vulvar Carcinoma. Gynecologic Oncology, 1994, 54, 393-395.	0.6	24